New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults ...

Early report Major update Updated Mar 6, 2026, 1:45 PM UTC

Track this event Edit in app More event pages

What changed

Early report surfaced from GlobeNewswire Public Companies 8h ago.

First seen Mar 6, 2026, 1:45 PM UTC Latest source Mar 6, 2026, 1:45 PM UTC

Update 1 8h ago

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

GlobeNewswire Public Companies •published Mar 6, 2026, 1:45 PM UTC •fetched Mar 6, 2026, 2:02 PM UTC

Event stats

Reports 1

Sources 1

Confidence low

Score 41

Entity focus

NewEnglandMedicineRocheGazyva

Source spread

GlobeNewswire Public Companies

Turn this into an alert

Draft the watch from the event wording, then let PushMe handle follow-up changes.

Notify me about major new developments on New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus, especi…

Create alert from this event